The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells

Anti-Cancer Drugs

Volumn 20, Issue 8, 2009, Pages 723-735

  Yde, Christina W ^a,b   Clausen, Mathias P ^a   Bennetzen, Martin V ^a   Lykkesfeldt, Anne E ^b   Mouritsen, Ole G ^a   Guerra, Barbara ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Breast cancer; Cell death; Chlorpromazine; Tamoxifen resistance

Indexed keywords

ANTIESTROGEN; CHLORPROMAZINE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; GLYCOPROTEIN P; LIPOSOME; TAMOXIFEN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIPID BILAYER; MEMBRANE PERMEABILITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA;

BINDING, COMPETITIVE; BREAST NEOPLASMS; CALORIMETRY, DIFFERENTIAL SCANNING; CELL DEATH; CELL LINE, TUMOR; CHLORPROMAZINE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ESTRADIOL; FEMALE; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; PERMEABILITY; PHASE TRANSITION; POLY(ADP-RIBOSE) POLYMERASES; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR STEM CELL ASSAY; UNILAMELLAR LIPOSOMES;

EID: 70349326002     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832ec041     Document Type: Article

References (42)

1. Lykkesfeldt AE. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Acta Oncol 1996; 35(Suppl 5):9-14.
2. Nicholson RI, Johnston SR. Endocrine therapy-current benefits and limitations. Breast Cancer Res Treat 2005; 93(Suppl 1):S3-S10.
3. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Cancer Lett 2007; 256:1-24.
4. Adams CE, Awad G, Rathbone J, Thornley B. Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev 2007; 2:CD000284.
5. Garver DL. Evolution of antipsychotic intervention in the schizophrenic psychosis. Curr Drug Targets 2006; 7:1205-1215.
6. Muraoka S, Miura T. Inactivation of cholinesterase induced by chlorpromazine cation radicals. Pharmacol Toxicol 2003; 92:100-104.
7. Sato S, Koshiro A. Pharmacokinetic analysis of chlorpromazine in rat serum, cerebrospinal fluid and striatum. Biol Pharm Bull 1995; 18:593-599.
8. Zhelev Z, Ohba H, Bakalova R, Hadjimitova V, Ishikawa M, Shinohara Y, et al. Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia. Cancer Chemother Pharmacol 2004; 53:267-275.
9. Gil-Ad I, Shtaif B, Levkovitz Y, Nordenberg J, Taler M, Korov I, et al. Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth. Oncol Rep 2006; 15:107-112.
10. Nordenberg J, Fenig E, Landau M, Weizman R, Weizman A. Effects of psychotropic drugs on cell proliferation and differentiation. Biochem Pharmacol 1999; 58:1229-1236.
11. Martins M, Dastidar SG, Fanning S, Kristiansen JE, Molnar J, Pages JM, et al. Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. Int J Antimicrob Agents 2008; 31:198-208.
12. Tsakovska I, Pajeva I. Phenothiazines and structurally related compounds as modulators of cancer multidrug resistance. Curr Drug Targets 2006; 7:1123-1134.
13. Ford JM, Hait WN. Pharmacologic circumvention of multidrug resistance. Cytotechnology 1993; 12:171-212.
14. Michalak K, Wesolowska O, Motohashi N, Molnar J, Hendrich AB. Interactions of phenothiazines with lipid bilayer and their role in multidrug resistance reversal. Curr Drug Targets 2006; 7:1095-1105.
15. Callaghan R, Higgins CF. Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br J Cancer 1995; 71:294-299.
16. Kayyali R, Marriott C, Wiseman H. Tamoxifen decreases drug efflux from liposomes: relevance to its ability to reverse multidrug resistance in cancer cells? FEBS Lett 1994; 344:221-224.
17. Lykkesfeldt AE, Sørensen EK. Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1. Acta Oncol 1992; 31:131-138.
18. Lykkesfeldt AE, Madsen MW, Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 1994; 54:1587-1595.
19. De Cremoux P, Tran-Perennou C, Brockdorff BL, Boudou E, Brünner N, Magdelenat H, et al. Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens. Endocr Relat Cancer 2003; 10:409-418.
20. Lundholt BK, Briand P, Lykkesfeldt AE. Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat 2001; 67:199-214.
21. Yde CW, Gyrd-Hansen M, Lykkesfeldt AE, Issinger OG, Stenvang J. Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. Mol Cancer Ther 2007; 6:1869-1876. (Pubitemid 46954064)
22. Heerklotz H, Seelig J. Titration calorimetry of surfactant-membrane partitioning and membrane solubilization. Biochim Biophys Acta 2000; 1508:69-85.
23. Leidy C, Linderoth L, Andresen TL, Mouritsen OG, Jørgensen K, Peters GH. Domain-induced activation of human phospholipase A2 type IIA: local versus global lipid composition. Biophys J 2006; 90:3165-3175.
24. Drori S, Eytan GD, Assaraf YG. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem 1995; 228:1020-1029.
25. Jørgensen K, Ipsen JH, Mouritsen OG, Bennett D, Zuckermann MJ. A general model for the interaction of foreign molecules with lipid membranes: drugs and anaesthetics. Biochim Biophys Acta 1991; 1062:227-238.
26. Agasøsler AV, Tungodden LM, Cejka D, Bakstad E, Sydnes LK, Holmsen H. Chlorpromazine-induced increase in dipalmitoylphosphatidylserine surface area in monolayers at room temperature. Biochem Pharmacol 2001; 61:817-825.
27. Trandum C, Westh P, Jørgensen K, Mouritsen OG. Association of ethanol with lipid membranes containing cholesterol, sphingomyelin and ganglioside: a titration calorimetry study. Biochim Biophys Acta 1999; 1420:179-188.
28. Wisniewska A, Wolnicka-Glubisz A. ESR studies on the effect of cholesterol on chlorpromazine interaction with saturated and unsaturated liposome membranes. Biophys Chem 2004; 111:43-52.
29. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2:101-112.
30. Phillips DH. Understanding the genotoxicity of tamoxifen? Carcinogenesis 2001; 22:839-849.
31. Wozniak K, Kolacinska A, Blasinska-Morawiec M, Morawiec-Bajda A, Morawiec Z, Zadrozny M, et al. The DNA-damaging potential of tamoxifen in breast cancer and normal cells. Arch Toxicol 2007; 81:519-527.
32. Bland AE, Calingaert B, Secord AA, Lee PS, Valea FA, Berchuck A, et al. Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol 2008; 112:150-154.
33. Morgan RW. Risk of endometrial cancer after tamoxifen treatment. Oncology (Huntingt) 1997; 11:25-33.
34. Clarke R, van den Berg HW, Murphy RF. Reduction of the membrane fluidity of human breast cancer cells by tamoxifen and 17 beta-estradiol. J Natl Cancer Inst 1990; 82:1702-1705.
35. Zeisig R, Koklic T, Wiesner B, Fichtner I, Sentjurc M. Increase in fluidity in the membrane of MT3 breast cancer cells correlates with enhanced cell adhesion in vitro and increased lung metastasis in NOD/SCID mice. Arch Biochem Biophys 2007; 459:98-106.
36. Bursch W, Ellinger A, Kienzl H, Torok L, Pandey S, Sikorska M, et al. Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 1996; 17:1595-1607.
37. Moreira PI, Custodio J, Moreno A, Oliveira CR, Santos MS. Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure. J Biol Chem 2006; 281:10143-10152.
38. Frogne T, Benjaminsen RV, Sonne-Hansen K, Sørensen BS, Nexø E, Laenkholm AV, et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009; 114:263-275.
39. Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL, Lykkesfeldt AE. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer 2005; 12:599-614.
40. Yde CW, Frogne T, Lykkesfeldt AE, Fichtner I, Issinger OG, Stenvang J. Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT. Cancer Lett 2007; 256:229-237. (Pubitemid 47418349)
41. Broniec A, Gjerde AU, Olmheim AB, Holmsen H. Trifluoperazine causes a disturbance in glycerophospholipid monolayers containing phosphatidylserine (PS): effects of pH, acyl unsaturation, and proportion of PS. Langmuir 2007; 23:694-699.
42. Wesolowska O, Hendrich AB, Motohashi N, Kawase M, Dobryszycki P, Ozyhar A, et al. Presence of anionic phospholipids rules the membrane localization of phenothiazine type multidrug resistance modulator. Biophys Chem 2004; 109:399-412.